Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

MLA

William D. Tap, et al. “Exposure-Response Relationship of Olaratumab for Survival Outcomes and Safety When Combined with Doxorubicin in Patients with Soft Tissue Sarcoma.” Cancer Chemotherapy and Pharmacology, vol. 83, no. 1, Sept. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....278fd4e3b474bc7146481fa3ab00bc79&authtype=sso&custid=ns315887.

APA

William D. Tap, John R. Baldwin, Patrick Peterson, Robert Ilaria, Ilaria Conti, Damien M. Cronier, Robin L. Jones, & Gary Mo. (2018). Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. Cancer Chemotherapy and Pharmacology, 83(1).

Chicago

William D. Tap, John R. Baldwin, Patrick Peterson, Robert Ilaria, Ilaria Conti, Damien M. Cronier, Robin L. Jones, and Gary Mo. 2018. “Exposure-Response Relationship of Olaratumab for Survival Outcomes and Safety When Combined with Doxorubicin in Patients with Soft Tissue Sarcoma.” Cancer Chemotherapy and Pharmacology 83 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....278fd4e3b474bc7146481fa3ab00bc79&authtype=sso&custid=ns315887.